Ensysce Biosciences (ENSCW) Change in Account Payables (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Change in Account Payables of -$579374.0 for Q3 2025, down 133.34% year-over-year from $1.7 million in Q3 2024, and down 235.51% quarter-over-quarter from $427537.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Change in Account Payables (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Change in Account Payables data on file, last reported at -$579374.0 in Q3 2025.
- Change in Account Payables for Q3 2025 came in at -$579374.0, down 133.34% year-over-year; the trailing twelve-month figure through Sep 2025 was -$1.4 million (down 292.39% YoY), and the FY2024 annual result was -$578928.0, up 53.1% from the prior year.
- Change in Account Payables eased to -$579374.0 in Q3 2025 per ENSCW's latest filing, from $427537.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $2.1 million in Q2 2022 and troughed at -$1.8 million in Q3 2022.
- A 5-year average of -$78297.1 and a median of -$323538.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2021 and 2022: Change in Account Payables tumbled 865.92% in 2021, then jumped 1071.15% in 2022.
- A 5-year view of Change in Account Payables shows it stood at -$170754.0 in 2021, then jumped by 1071.15% to $1.7 million in 2022, then sank by 52.17% to $793088.0 in 2023, then tumbled by 165.73% to -$521262.0 in 2024, then declined by 11.15% to -$579374.0 in 2025.
- Business Quant data shows ENSCW's Change in Account Payables at -$579374.0 in Q3 2025, $427537.0 in Q2 2025, and -$741784.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -579,374.00 |
| Sep 30, 2025 | -579,374.00 |
| Jun 30, 2025 | 427,537.00 |
| Jun 30, 2025 | 427,537.00 |
| Mar 31, 2025 | -741,784.00 |
| Mar 31, 2025 | -741,784.00 |
| Dec 31, 2024 | -521,262.00 |
| Dec 31, 2024 | -521,262.00 |
| Sep 30, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | -499,749.00 |
| Jun 30, 2024 | -499,749.00 |
| Mar 31, 2024 | -1.30 Mn |
| Mar 31, 2024 | -1.30 Mn |
| Dec 31, 2023 | 793,088.00 |
| Dec 31, 2023 | 793,088.00 |
| Sep 30, 2023 | -358,213.00 |
| Sep 30, 2023 | -358,213.00 |
| Jun 30, 2023 | -323,538.00 |
| Jun 30, 2023 | -323,538.00 |